Blood pressure control is one of the most important aspects of cardiovascular disease management because numerous studies have demonstrated the benefits of lowering blood pressure to prevent stroke, heart failure, and other cardiovascular events. Persons with chronic kidney disease (CKD) frequently have hypertension, and recent guidelines from KDIGO (Kidney Disease: Improving Global Outcomes) and the Eighth Joint National Committee (JNC 8) address the issues of antihypertensive agents and blood pressure targets. JNC 8 recommends a blood pressure goal < 140/90 mm Hg for patients with CKD, whereas KDIGO recommends a target blood pressure < 130/ 80 mm Hg for patients with CKD with proteinuria. JNC 8 guidelines recommend renin-angiotensin system antagonists as the preferred agents in all patients with CKD, whereas KDIGO recommends them as preferred agents only in patients with proteinuria.
展开▼
机译：血压控制是心血管疾病管理的最重要方面之一，因为许多研究表明降低血压对预防中风，心力衰竭和其他心血管事件的益处。慢性肾脏病（CKD）患者经常患有高血压，KDIGO（肾脏病：改善全球疗效）和第八届全国联合委员会（JNC 8）的最新指南解决了降压药和血压目标的问题。 JNC 8建议CKD患者的血压目标<140/90 mm Hg，而KDIGO建议CKD蛋白尿的患者目标血压<130/80 mm Hg。 JNC 8指南建议将肾素-血管紧张素系统拮抗剂作为所有CKD患者的首选药物，而KDIGO建议仅将其作为蛋白尿患者的首选药物。
展开▼
